I don't know what others think about this, but I remember having the flu vaccine way back in the 60s when it first came out the whole school was done and I reckon we were an 'experiment' ... quite a few of us went down with real proper flu directly after the vaccine I got it both years I had the vaccination and flatly refused to have it again after that, even though my parents had given permission .
INTERESTING, distribute widely! Protect us and especially avoid the fear that can only bring problems later! Nurses speak out! While we are at the dawn of a mandatory vaccination, Read carefully, and to relay to your friends, because the media will not report in order not to harm the lobbies of laboratories.
The View of the French[url=Http:
//www.
syndicat-infirmier.
com/Vaccination-H1N1-mefiance-des.
html:37ipmyos]
[You must be registered and logged in to see this link.]"
Vaccination H1N1: distrust of nurses Our nursing duty is to properly inform people so that each can take their decision knowingly, with free and informed consent, not by an advertising campaign and alarmist speeches "
. Read absolument.MerciEdith
Translation of link: The nurses' union SNPI CFE-CGC considers that mass vaccination against a relatively benign influenza virus , is a risk because the vaccine was developed too quickly, and an adjuvant can trigger autoimmune diseases.
We invite the population to be vaccinated against seasonal influenza vaccine;
this (produced under normal conditions) is available from the fourth week of September. This will quickly make a differential diagnosis in cases of influenza-like illness. By cons, everyone must accurately measure the benefit / risk of the H1N1 vaccine: one side a week of flu, the other a chance, but ultimately weak, of having a neurological disease (Guillain-Barre syndrome) or self -immune deficiency.
As our nursing colleagues in Britain and Hong Kong, we fear that the cure may be worse than the disease, and we think you need to know "
keep right"
( some facts? AD). The pandemic could cause an economic crisis and the state was very well organized to deal with (health advice, masks, Tamiflu). "
But inject 94 million doses of a product on which we have no recoil (information? AD) can be a public health problem, and it is our duty as nurses to properly inform people so that each individual takes its decision knowingly, by a free and informed consent, and not by an advertising campaign and alarmist reporting "
said Thierry Amouroux, the Secretary General of SNPI, the National Union of Professional Nurses.
The H5N1 virus responsible for avian flu, had a very high virulence (mortality rate reached 60%) coupled with a very low contagion among humans (several thousands of cases throughout the world). The H1N1 is almost the opposite: it is highly contagious but only slightly aggressive: in France, 2 deaths in patients with severe chronic diseases and carriers of influenza A (H1N1), and 11 serious cases against about 2,000 dead in France from seasonal influenza per year! According INVS at 25.08.09, 85 deaths have been reported in Europe since the beginning of the epidemic, including 59 in the United Kingdom and 16 in Spain.
According to the interministerial crisis committee met Thursday, August 27, 2009, to the Epidemic of Influenza A: "
The unknowns still remaining include: the date of delivery of vaccines by manufacturers, the date of AMM and its perimeter (adults, children, pregnant women ...), the precise definition of those at risk and the fatality rate of influenza virus A (H1N1). "
Deaths during a seasonal influenza is usually associated with decompensation of chronic diseases and secondary bacterial infection, there is no evidence today that these indirect complications are more frequent with influenza A (H1N1).
Risk of Guillain-Barre Syndrome GBSThe Guillain-BarrÃÂ
is a kind of ascending paralysis that begins in the lower limbs to climb gradually. In severe cases it may be complicated by paralysis of respiratory muscles and the person affected will then be placed on a respirator. The paralysis may be irreversible.
How can we avoid a repeat of the complications encountered in 1976 in the United States of America with the vaccine against swine flu? 46 million people were vaccinated, and about 4,000 of them complained afterwards to serious side effects. According to the WHO studies suggest that regular vaccination against seasonal flu could be associated with an increased risk of Guillain-Barre of the order of one to two cases per million vaccinees. During the influenza vaccination campaign of 1976, this risk has increased to about ten cases per million people vaccinated, which led to a withdrawal of the vaccine.
A vaccine against swine flu has again been associated with an increased risk of GBS in 1993-1994. The Americans were then recorded 74 cases of GBS in 1994, up sharply on 1993 (37 cases).
"
We are quite aware of the risk associated with the occurrence of cases of Guillain-BarrÃÂ
patients vaccinated against influenza,"
said Carmen Kreft-Jais, head of pharmacovigilance at the French Agency for Sanitary Safety of Health Products ( Afssaps) in an article in Le Monde of 20.08.09. We follow closely the evolution of the number of Guillain-Barre pandemic and mass vaccination. "
Specific regulatory procedures have been designed to expedite the approval of vaccines against pandemic influenza. According to WHO, "
specific questions about the safety of vaccines against flu pandemic inevitably arise when we begin to administer a large scale. For example, adverse events, too rare to be highlighted even in clinical trials of major, can occur when the vaccination for very large populations. According to WHO, "
for lack of time, clinical data will inevitably be limited when it will begin administering vaccines against influenza pandemic. Testing safety and effectiveness should therefore be continued after starting to administer.
Problems of the H1N1 vaccine adjuvantAn adjuvant is a chemical that is used to make the vaccine more effective and can afford to use a dose of antigen lower. The question is whether the potential impact of a new adjuvant on autoimmune diseases which are caused precisely by a disruption of the immune system.
An adjuvant, AS03 used for the vaccine developed by GlaxoSmithKline (GSK), allows to use very low doses of antigen, thus multiplying the number of doses possible. The surveillance system is in place will ensure that people with autoimmune disease (diabetes, hypothyroidism, arthritis, multiple sclerosis, etc..) Will not see their problems worsen.
The H1N1 vaccine contains 10 times less antigen (for faster production, given the quantities to be produced quickly) through the presence of the adjuvant AS03, an amplifier effect which is a mixture of squalene and polysorbate.
This adjuvant has previously been used in a vaccine marketed widely, and can trigger excessive immune responses and increase the likelihood and frequency of rare, but serious and dangerousvside effects, such as Guillain -Barre.
The additives and adjuvants may affect the safety of vaccines so are completely unpredictable, as we have seen for example with the vaccine meningo-enchÃÂ
phalite tick TICOVAC, which has been withdrawn from the market in 2001, barely 14 months after its launch, due to serious and frequent side effects . The composition of Ticovac differed from that of its predecessor by only two additives that have been eliminated since: albumin and a preservative containing mercury. Therefore the product is banned in Germany, France and the dosage was halved, and the indication was withdrawn in children under 3 years. (details in the conclusions of the Commission on transparency of the High Authority of Health.
Why not continue to rely on the conventional production methods proven by decades of experience with vaccines against seasonal influenza?For, unlike these conventional vaccines, widespread use of vaccines containing new substances which enhance the immune response is problematic:
Our experience and our knowledge of adjuvant amplifying the immune response is very low, and every pharmaceutical company uses its own mix, for which it holds patents.
The portion of clinical trials to routine administration is a particularly sensitive phase in the use of drugs. If it has unexpected side effects, they may affect a large number of people before we can go back. Immediate vaccination of tens of millions of people with a vaccine being tested ( not fully tested and still at the experimental stage? AD) is slightly worrying is an experimental scale.
The stimulation of the immune system by three doses of influenza vaccine in a few weeks is a novelty, seasonal influenza in September, then two doses of pandemic vaccine adjuvant three weeks apart